Quantcast

Latest Natalizumab Stories

7d6c5e2a2a65ac0a0e019d7364038c9d1
2008-12-15 14:42:08

On Monday, Biogen Idec Inc said it notified regulators of a new case of a potentially deadly brain disease in a patient being treated with its Tysabri multiple sclerosis drug, the fourth such case reported globally this year. Biogen stated in a regulatory filing that the latest case of the brain infection, known as progressive multifocal leukoencephalopathy (PML), was seen in a European patient that had been taking Tysabri as a stand-alone treatment for 26 months. Company spokeswoman Shannon...

2008-12-01 07:00:00

Increased Uptake of Current Agents and Emergence of New Therapies Will Drive Robust Annual Market Growth, According to a New Report from Decision Resources WALTHAM, Mass., Dec. 1 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Abbott/Eisai's Humira is poised to overtake Centocor/Schering-Plough/Mitsubishi Tanabe's Remicade as the Crohn's disease market leader by 2012. Humira will retain its...

7cd9b33c5a9ef0f5162dff94b3de14c71
2008-11-24 11:40:00

On Monday Italian researchers said a faulty immune reaction may be responsible for the development of epilepsy. The researchers used mice and found that seizures are linked to brain changes, which made immune cells stick inside its blood vessels. This helped break down a vital filter which protects the brain from harmful chemicals. "Unsticking" these cells helped prevent the development of epilepsy in mice. This finding could lead to preventing about 1 percent of the general population...

2008-11-03 12:00:26

PatientsLikeMe, the leading online community for patients with life-changing conditions, announces the release of its newest PatientsLikeMeListen(TM) report: "Did the July 2008 PML announcement affect the Tysabri brand?" Among its findings, the report reveals that patients retained an overall positive perception of the Tysabri brand despite the July 2008 announcement of two additional PML cases. "In light of last week's announcement of an additional case of PML in a Tysabri patient, we felt...

2008-10-31 00:00:20

Biogen Idec Inc. says a U.S. woman contracted a deadly brain infection while taking the drug Tysabri. The drug maker said the woman contracted progressive multifocal leukoencephalopathy, or PML, while taking the drug alone rather than in conjunction with other drugs, The Wall Street Journal reported Thursday. The U.S. Food and Drug Administration said in August that using Tysabri alone may confer a lower risk of PML than when the drug is used together with other immunomodulatory...

69f96049fb2993a4f81399f887bdfe8d1
2008-10-23 15:56:08

A drug developed for patients with leukemia also appears to regenerate brain cells and reverse the effects of relapsing-remitting multiple sclerosis, British researchers said on Wednesday. Bayer AG and Genzyme Corp's alemtuzumab, marketed under the brand name Campath, showed long-term improvement in disability in a three-year study, said Alasdair Cole, a neurologist at the University of Cambridge. Multiple sclerosis is an autoimmune condition in which the immune system damages the central...

2008-10-23 12:00:00

Genzyme and Bayer have reported Phase II study results demonstrating the potential of alemtuzumab in treatment-naive MS patients. Although the product's efficacy is now established, two recently initiated Phase III trials will reveal whether alemtuzumab should be used as an early treatment or if safety issues will restrict it to patients who continue to relapse on currently approved MS therapies. Results from the final three-year analysis of the 334-patient CAMMS223 study showed that...

2008-09-19 15:00:12

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that a post-hoc analysis showed TYSABRI(R) (natalizumab) treatment increases the probability of achieving sustained improvement in physical disability over two years when compared to placebo. This post-hoc analysis provides the first evidence that TYSABRI is associated with a significant improvement in functional outcome, rather than only slowing or preventing progression of disability, in those living with relapsing...

2008-09-18 15:00:38

Biogen Idec (NASDAQ: BIIB) today announced that data was presented from the ASSURANCE (ASSessment of Drug Utilization, EaRly TreAtmeNt, and Clinical OutcomEs) study, showing the long-term benefits of AVONEX(R) (interferon beta-1a IM) therapy in patients with relapsing multiple sclerosis (MS) for up to 15 years. The ASSURANCE study represents the long-term follow-up of patients who participated in the Multiple Sclerosis Collaborative Research Group (MSCRG), the original Phase III pivotal trial...

2008-09-18 09:00:49

Biogen Idec (NASDAQ: BIIB) will present new data on the company's leading multiple sclerosis (MS) franchise at the World Congress on Treatment and Research in Multiple Sclerosis taking place this week in Montreal, Canada. Nearly 20 presentations will focus on the company's products: TYSABRI(R) (natalizumab), which offers MS patients a new level of efficacy, and AVONEX(R) (Interferon beta-1a), the most prescribed MS therapy worldwide, as well as its pipeline featuring compounds targeting...


Word of the Day
call-note
  • The call or cry of a bird or other animal to its mate or its young.
'Call-note' is newer than 'bird-call,' which originally referred to 'an instrument for imitating the note of birds' but now also refers to 'the song or cry of a bird.'
Related